Efficacy News and Research

RSS

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Infant deaths in clinical drug trials in India raise concern about ethical standards

The revelation that 49 babies died at a top Indian hospital during drug tests has shocked many and raised issues concerning ethical standards at the hospital.

25 Aug 2008

Cymbalta approved in Europe for generalised anxiety disorder

Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD).

24 Aug 2008

New imaging technology provides early diagnosis of osteoarthritis

A newly developed medical imaging technology may provide doctors with a long-awaited test for early diagnosis of osteoarthritis (OA), scientists from New York reported today at the 236th National Meeting of the American Chemical Society.

20 Aug 2008

Addiction drug Vigabatrin proves successful in animal weight loss study

Vigabatrin, a medication proposed as a potential treatment for drug addiction by scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, also leads to rapid weight loss and reduced food intake according to a new animal study from the same research group.

20 Aug 2008

Alternative vaccine strategy shows promise in prostate cancer patients

New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.

17 Aug 2008

Sngle-walled carbon nanotubes used as cancer drug delivery vehicles

The problem with using a shotgun to kill a housefly is that even if you get the pest, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.

14 Aug 2008

Managing diabetes at school

The first ever UK study to seek the opinions of young people with type 1 diabetes, regarding managing their diabetes care at school, uncovered a number of significant misconceptions about the condition.

14 Aug 2008

New drug targets main culprit in common colds

The Melbourne drug company Biota has announced trials of a drug to treat the human rhinovirus (HRV) which is the main culprit in the common cold.

12 Aug 2008

Oxygen Biotherapeutics develops gel version of Oxycyte for treating surface wounds

Oxygen Biotherapeutics, Inc. has announced that the company has developed a gel-like form of Oxycyte that it intends to investigate as a topical application for open wounds, abrasions and burns. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

12 Aug 2008

Luminaries call for continued support for an AIDS vaccine to end the epidemic

Discussions about how to manage AIDS in the long term and how to improve prevention efforts globally took center stage at this year's International AIDS Conference (IAC) held in Mexico City.

10 Aug 2008

FDA warns consumers about Baltimore Medicine Shoppe pharmacies

The U.S. Food and Drug Administration is warning consumers who filled prescriptions at The Medicine Shoppe pharmacies located at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received drugs that were either expired or suspected counterfeit.

10 Aug 2008

Medicinal cannabis effective for neuropathic pain in HIV

In a double-blind, placebo-controlled clinical trial to assess the impact of smoked medical cannabis, or marijuana, on the neuropathic pain associated with HIV, researchers at the University of California, San Diego School of Medicine found that reported pain relief was greater with cannabis than with a placebo.

6 Aug 2008

USPTO issues patent for methodologies for abating a broad range of allergens, pathogens, viruses, bacteria

The United States Patent & Trademark Office issued a patent for an environmentally "Green" low cost process that eliminates the effects of a broad range of pollutants using oxidants.

5 Aug 2008

Maternal deaths following cesarean delivery can be reduced

Maternal death rates have remained constant in the United States for many decades. Are there any improvements in health care that could reduce these rates further?

4 Aug 2008

U.S. EPA calls out nation's largest manufacturer of hospital disinfectants

Consumers should never have to second-guess information on product labels, and through a recent settlement between the U.S. Environmental Protection Agency (EPA) and Lonza Inc., the nation's largest manufacturer of hospital disinfectants, consumers will now assuredly be getting what they pay for.

4 Aug 2008

ShangRing - innovative circumcision device

With the recent endorsement by the World Health Organization (WHO) and scientists worldwide of adult male circumcision as an important strategy for HIV prevention, there is increased urgency to develop safe and cost-effective circumcision services. This is especially the case in Africa where HIV/AIDS continues to spread at an epidemic rate.

4 Aug 2008

Immunotherapy shows promise in high-risk pediatric sarcomas

Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer.

3 Aug 2008

Fatal flaws in the way new drugs are tested and marketed

Americans are likely to be exposed to unacceptable side effects of FDA-approved drugs such as Vioxx in the future because of fatal flaws in the way new drugs are tested and marketed, according to research to be presented at the annual meeting of the American Sociological Association (ASA).

3 Aug 2008

New studies examine use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C

Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

31 Jul 2008